Skip Navigation



Annals of Oncology Advance Access published online on July 27, 2006
Annals of Oncology, doi:10.1093/annonc/mdl168
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/10/1529    most recent
mdl168v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Orditura, M.
Right arrow Articles by De Vita, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Orditura, M.
Right arrow Articles by De Vita, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology
Received April 30, 2006
Revised June 15, 2006
Accepted June 16, 2006

original article

Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study

M. Orditura 1, E. Martinelli 1, G. Galizia 2, C. Carlomagno 3, G. Aurilio 1, L. Vecchione 1, Eva Lieto 2, S. De Placido 3, G. Catalano 1, F. Ciardiello 1, and F. De Vita 1 *

1 Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale 'F. Magrassi e A. Lanzara Cattedra di Oncologia Medica
2 Cattedra di Chirurgia Generale ed Epatobiliare, Seconda Università degli Studi di Napoli
3 Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Università Federico II Napoli, Naples, Italy

* To whom correspondence should be addressed.
F. De Vita, E-mail: fernandodevita{at}yahoo.it


  Abstract

Background: Capecitabine and docetaxel have demonstrated preclinical antitumor synergy and activity in advanced gastric cancer. We assessed the clinical activity and the toxicity of weekly docetaxel in combination with capecitabine in untreated patients with advanced gastric cancer.

Patients and methods: A total of 38 patients were treated with docetaxel 36 mg/m2 on days 1, 8, and 15 i.v., plus capecitabine, 625 mg/m2 bid per os on days 5 to 18 repeated every 4 weeks.

Results: All patients were assessable for response to treatment and for toxicity. Major responses were observed in eight patients (21%), with three patients achieving a CR (7.8%) and five showing a PR (13%). The median time to progression was 5.4 months and the overall survival was 7.7 months. The safety profile of this schedule was acceptable with a low rate of myelossuppression, diarrhoea and hand-foot syndrome.

Conclusions: The combination of docetaxel and capecitabine at the doses and schedule investigated in this study is safe, but does not show significant activity in untreated patients with advanced gastric cancer.

Keywords: docetaxel; capecitabine; gastric cancer.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.